Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregor Schweighofer-Zwink

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Clinical Nuclear Medicine|August 18, 2020
Para-aortal Ganglion Mimicking a Lymph Node Metastases on 68Ga-PSMA PET/CTGregor Schweighofer Zwink, Gundula Rendl, Nikolaus Schmeller, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|March 28, 2020
Pre-Ablation rhTSH-Stimulated F-18 FDG PET/CT Changes Patient Management in Increased-Risk Thyroid CancerGundula Rendl, Lukas Rettenbacher, Gregor Schweighofer-Zwink, et al.
Clinical Nuclear Medicine|March 1, 2024
18F-FDG and 68Ga-PSMA PET/CT in Paratesticular MesotheliomaForough Kalantari, Gregor Schweighofer-Zwink, Gundula Rendl, et al.
EJNMMI Reports|January 5, 2025
B-CLL with negative <sup>18</sup>F-FDG PET/CT and intensive solitary lesion on PSMA PET/CT mimicking prostate cancer bone metastasesTheresa Jung, Daniel Neureiter, Gregor Schweighofer-Zwink, et al.
Skeletal Radiology|January 26, 2020
Evaluation of baseline fracture risk in younger postmenopausal women with breast cancer using different risk assessment methodsDagmar Schaffler-Schaden, Christoph Kneidinger, Gregor Schweighofer-Zwink, et al.
Wiener Medizinische Wochenschrift (1946)|September 29, 2018
[Imaging of parathyroid adenomas with F‑18 choline PET-CT]Gregor Schweighofer-Zwink, Lukas Hehenwarter, Gundula Rendl, et al.
EJNMMI Research|May 2, 2021
Feasibility of equivalent performance of 3D TOF [<sup>18</sup>F]-FDG PET/CT with reduced acquisition time using clinical and semiquantitative parametersJulia Pilz, Lukas Hehenwarter, Georg Zimmermann, et al.
Cancers|April 23, 2022
Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria-Which One Is Most Suitable?Gundula Rendl, Gregor Schweighofer-Zwink, Stefan Sorko, et al.
European Journal of Radiology|December 18, 2021
Prognostic value of 2-[<sup>18</sup>F]FDG PET-CT in metastatic melanoma patients receiving immunotherapyGregor Schweighofer-Zwink, Reyhaneh Manafi-Farid, Peter Kölblinger, et al.
Cancers|November 13, 2021
Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future TrendsReyhaneh Manafi-Farid, Shaghayegh Ranjbar, Zahra Jamshidi Araghi, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Clinical Nuclear Medicine|August 18, 2020
Para-aortal Ganglion Mimicking a Lymph Node Metastases on 68Ga-PSMA PET/CTGregor Schweighofer Zwink, Gundula Rendl, Nikolaus Schmeller, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|March 28, 2020
Pre-Ablation rhTSH-Stimulated F-18 FDG PET/CT Changes Patient Management in Increased-Risk Thyroid CancerGundula Rendl, Lukas Rettenbacher, Gregor Schweighofer-Zwink, et al.
Clinical Nuclear Medicine|March 1, 2024
18F-FDG and 68Ga-PSMA PET/CT in Paratesticular MesotheliomaForough Kalantari, Gregor Schweighofer-Zwink, Gundula Rendl, et al.
EJNMMI Reports|January 5, 2025
B-CLL with negative <sup>18</sup>F-FDG PET/CT and intensive solitary lesion on PSMA PET/CT mimicking prostate cancer bone metastasesTheresa Jung, Daniel Neureiter, Gregor Schweighofer-Zwink, et al.
Skeletal Radiology|January 26, 2020
Evaluation of baseline fracture risk in younger postmenopausal women with breast cancer using different risk assessment methodsDagmar Schaffler-Schaden, Christoph Kneidinger, Gregor Schweighofer-Zwink, et al.
Wiener Medizinische Wochenschrift (1946)|September 29, 2018
[Imaging of parathyroid adenomas with F‑18 choline PET-CT]Gregor Schweighofer-Zwink, Lukas Hehenwarter, Gundula Rendl, et al.
EJNMMI Research|May 2, 2021
Feasibility of equivalent performance of 3D TOF [<sup>18</sup>F]-FDG PET/CT with reduced acquisition time using clinical and semiquantitative parametersJulia Pilz, Lukas Hehenwarter, Georg Zimmermann, et al.
Cancers|April 23, 2022
Assessment of Treatment Response to Lenvatinib in Thyroid Cancer Monitored by F-18 FDG PET/CT Using PERCIST 1.0, Modified PERCIST and EORTC Criteria-Which One Is Most Suitable?Gundula Rendl, Gregor Schweighofer-Zwink, Stefan Sorko, et al.
European Journal of Radiology|December 18, 2021
Prognostic value of 2-[<sup>18</sup>F]FDG PET-CT in metastatic melanoma patients receiving immunotherapyGregor Schweighofer-Zwink, Reyhaneh Manafi-Farid, Peter Kölblinger, et al.
Cancers|November 13, 2021
Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future TrendsReyhaneh Manafi-Farid, Shaghayegh Ranjbar, Zahra Jamshidi Araghi, et al.
Pageof 3